Thursday, January 11, 2024 | 6:15 pm – 7:15 pm
Discover an Oral Treatment for Severe Alopecia Areata
E. Ted Lain, MD
Sponsored by Pfizer
Room: Floridian KL
This is a non-CME/CE presentation.
Program Summary: Discover an oral treatment for severe alopecia areata. Pfizer Inc., invites you to an engaging, non-CME, educational program that will cover the efficacy and safety of an FDA-approved treatment option.
Friday, January 12, 2024 | 7:45 am – 8:45 am
Make SILIQ Your Bio-Logical Next Step
E. Ted Lain, MD
Sponsored by Ortho Dermatologics
Room: Floridian KL
This is a non-CME/CE presentation.
Friday, January 12, 2024 | 12:30 pm – 1:30 pm
A Targeted Approach to the Treatment of Nonsegmental Vitiligo
Heather Woolery-Lloyd, MD, FAAD
Sponsored by Incyte
Room: Floridian KL
This is a non-CME/CE presentation.
Friday, January 12, 2024 | 12:30 pm – 1:30 pm
An IL-23 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Leon Kircik, MD
Sponsored by Sun Pharma
Room: Floridian J
This is a non-CME/CE presentation.
Program Summary: Please join us for a Product Theatre with Dr. Leon Kircik entitled: LUMYA® (tildrakizumab-asmn): Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence.
Saturday, January 13, 2024 | 7:15 am – 8:15 am
VISIBLE Results Across All Skin Tones with TREMFYA
Andrew Dorizas, MD
Sponsored by Janssen
Room: Floridian KL
This is a non-CME/CE presentation.
Program Summary: A comprehensive program that walks through the unmet need in PsO, clinical innovations of VISIBLE, a first-of-its-kind study to measure clearance objectively in all skin tones with TREMFYA®, and cohort A data from the study.
Saturday, January 13, 2024 | 7:15 am – 8:15 am
VTAMA® (tapinarof) cream, 1%: Phase 4 Open-Label Trial for the Treatment of Intertriginous Plaque Psoriasis
Ben Lockshin, MD
Sponsored by Dermavant
Room: Floridian J
This is a non-CME/CE presentation.
Saturday, January 13, 2024 | 12:45 pm – 1:45 pm
Mild to Moderate Atopic Dermatitis and the JAK-STAT Pathway
Adam Friedman, MD
Sponsored by Incyte
Room: Floridian KL
This is a non-CME/CE presentation.
Program Summary: Join Dr Friedman for an informative session on mild to moderate atopic dermatitis and an examination of the efficacy and safety of a potential treatment option.
Saturday, January 13, 2024 | 12:45 pm – 1:45 pm
Learn More About SOTYKTU™ (deucravacitinib): Clinical Trial Data and Mechanism of Action
Leon Kircik, MD
Sponsored by BMS
Room: Floridian J
This is a non-CME/CE presentation.
Program Summary: This program describes the efficacy and safety profile of an oral product. You will learn more about the pivotal clinical trials, product function, and patient support services.
Saturday, January 13, 2024 | 3:30 pm – 4:30 pm
The Latest Approved Indication for COSENTYX® (secukinumab)
Ellen Menefee, PA-C, DMSc
Sponsored by Novartis
Room: Floridian KL
This is a non-CME/CE presentation.
Program Summary: Novartis Pharmaceuticals Corporation invites to you attend an informative session on the latest approved indication for Cosentyx® (secukinumab)
Saturday, January 13, 2024 | 6:00 pm – 7:00 pm
Exploring The Ever Evolving Full Skin Tone Spectrum: Not Just Another SOC Lecture
Misty Eleryan, MD, MS, FAAD, ACMS and Adam Friedman, MD
Sponsored by AbbVie
Room: Floridian J
This is a non-CME/CE presentation.
Program Summary: This program focuses on improving identification of skin disease across the full skin tone spectrum. The speakers will share several patient cases, focusing on atopic dermatitis (AD), hidradenitis suppurativa (HS), and psoriasis (PsO), among other diseases, and will highlight visual presentation. Through live polling, the program will engage the audience in discussion surrounding the diagnosis of these patients. The speakers will provide suggestions for what the medical community can do to work toward better diagnosis and treatment for patients across the full skin tone spectrum
Saturday, January 13, 2024 | 6:00 pm – 7:00 pm
Managing Atopic Dermatitis & Xerosis in Skin of Color Patients with Prebiotic Skincare
Timothy Corcoran Flynn, MD and Hawasatu Dumbuya, PhD
Sponsored by La Roche-Posay
Room: Floridian KL
This is a non-CME/CE presentation.
Sunday, January 14, 2024 | 1:15 pm – 2:15 pm
A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Adam Friedman, MD
Sponsored by Sanofi-Regeneron Pharmaceuticals, Inc.
Room: Floridian KL
This is a non-CME/CE presentation.
Program Summary: Learn more about a treatment option that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis and prurigo nodularis.